An Investigation Of The Impact Of Novel Gene LAPTM4B Expression On The Histopathology, Metastasis And Prognosis Of Ovarian Cancer

Objective: This is the first study to investigate the association betweenLAPTM4B-35expression and ovarian cancer with and without lymph node metastasis.The associations between LAPTM4B-35and the pathology, metastasis, chemotherapyresistance and prognosis in ovarian cancer also are discussed in this research.Methods: Immunoblotting: LAPTM4B1-99-pAb was used to detect theLAPTM4B-35expression in patients with normal ovaries, benign ovarian tumors andovarian cancers.Immunohistochemical Staining: LAPTM4B1-99-pAb was used to detect theLAPTM4B-35expression in patients with primary ovarian cancer, intraperitonealmetastasis and lymph node metastasis. In addition, the relations betweenLAPTM4B-35expression and the clinical characteristics of patients, metastasis andresistance also were evaluated.Survival analysis: Survival rates were estimated using the Kaplan-Meier method.Log-rank test and Cox regression analysis were used in univariate and multivariateanalysis, respectly.Results: Thirty frozen tissue sections of ovarian cancers and ten frozen tissuesamples of normal ovaries were analyzed by immunoblotting to detect theLAPTM4B-35expression. Normal ovaries displayed almost negative expression andhigh expression was detected in ovarian cancers.LAPTM4B-35expression was found to have associations with FIGO stage and histopathological differentiation by immunoblotting. It was shown that LAPTM4B-35expression was closely related to epithelial ovarian carcinoma metastasis. Among59patients with LAPTM4B overexpression,57(96.6%) had intraperitoneal metastasisand31(52.5%) had lymph node metastasis. For intraperitoneal metastasis, thesensitivity and specificity of LAPTM4B-35overexpression were48.7%and90.9%;for lymph node metastasis, they were73.8%%and71.1%, respectively. The positivepredictive value was52.5%(31/59) and the negative predictive value was86.3%(69/80). This study showed that LAPTM4B-35expression was an independent factorin ovarian cancer chemotherapy resistance. The sensitivity and specificity ofLAPTM4B overexpression were97.8%and47.06%for the diagnosis of epithelialovarian carcinoma. Among139patients with LAPTM4B-35overexpression,80patients were LAPTM4B-35low-expression and59patients were LAPTM4B-35high-expression. Univariate statistical analysis showed that the differences of thefive-year overall survival (OS) rates and the five-year progression-free survival (PFS)rates between patients with high LAPTM4B expression and low LAPTM4Bexpression were both statistically significant. Multivariate statistical analysis showedthat LAPTM4B over-expression is an independent factor in epithelial ovariancarcinoma prognosis(OS: HR=21.304,95%CI:6.260-72.502,Ｐ<.0001; DFS: HR=16.043,95%CI:5.935-43.367, Ｐ<.0001).Conclusion:1. LAPTM4B-35expression is associated with clinicalcharacteristics of patients with epithelial ovarian carcinoma.2. LAPTM4B overexpression is a new predictor of epithelial ovarian carcinomametastasis and chemotherapy resistance, and it may be an important potentialbiomarker for the early diagnosis of ovarian carcinoma.3. LAPTM4B overexpression is a new biomarker of epithelial ovarian carcinomaprognosis. LAPTM4B-35high-expression suggests poor prognosis of epithelialovarian carcinoma.